Boston Scientific Corporation announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease.

Boston Scientific Corporation today announced Health Canada approval of the Blazer Open-Irrigated Catheter, the Company's latest radiofrequency ablation (RFA) catheter designed to treat a variety of arrhythmias such as atrial fibrillation, atrial flutter, ventricular tachycardia and other supraventricular tachycardias.

Boston Scientific Corporation reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the Company's Epic Self-Expanding Nitinol Stent System in patients with iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow.

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced Unity Lab Services, a new offering that combines product and laboratory support services to create a single solution for customers to optimize productivity and reduce their total cost of laboratory operations.

The Intellectual Property portfolio of TIGR Matrix Surgical Mesh has been further complimented with the granting of a second U.S. patent related to material degradation and mechanical behaviour.

Manhattan Scientifics announced today that "Breast Cancer Research," an international, peer-reviewed online journal, has published results of a study using Senior Scientific's nanomagnetic technology.

Manhattan Scientifics announced today that the National Cancer Institute (NCI) has funded a grant for its Senior Scientific, LLC unit, for the use of its proprietary, highly precise magnetic cancer cell measurement in leukemia research for determining the progress of cancer treatment.

Boston Scientific Corporation has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial. NECTAR-HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.

Boston Scientific Corporation's WallFlex Biliary RX Fully Covered Stent has received Health Canada approval for the treatment of benign biliary strictures, which supplements its current indication for management of malignant biliary strictures.

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

Boston Scientific Corporation (NYSE: BSX) announced several milestones in the adoption of its SpyGlass® Direct Visualization System since its worldwide launch in July 2007. The SpyGlass System guides visualization and accessory devices for diagnostic and therapeutic procedures in the pancreatico-biliary system, including the hepatic ducts. It was developed ...

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Clik™ Anchor for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the world's first rechargeable SCS device for chronic pain management. The Clik Anchor features an innovative locking system designed to improve ...